Last mentioned: Feb 27, 2026
Crinetics Pharmaceuticals (CRNX) reported Q4 2025 results, highlighting critical progress in its endocrine pipeline and preparations for the commercial launch of paltusotine. Alongside results from MDxHealth and Baldwin, the earnings cluster reflects a strategic transition for mid-cap healthcare and service firms navigating the 2026 market landscape.
This page surfaces every story mentioning MDxHealth SA across our finance coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running finance beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where MDxHealth SA was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |